Pulmonary exacerbations in cystic fibrosis

被引:87
作者
Stenbit, Antine E. [1 ]
Flume, Patrick A. [1 ,2 ]
机构
[1] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA
关键词
cystic fibrosis; hemoptysis; pulmonary exacerbation; BRONCHIAL ARTERY EMBOLIZATION; QUALITY-OF-LIFE; PSEUDOMONAS-AERUGINOSA; RESPIRATORY-FAILURE; CF PATIENTS; HEMOPTYSIS; GUIDELINES; COMBINATION; ADULTS; SPUTUM;
D O I
10.1097/MCP.0b013e32834b8c04
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose of review The chronic infection and inflammation of cystic fibrosis (CF) lung disease causes a progressive decline of lung function resulting in daily symptoms such as cough and sputum production. There are intermittent episodes of acute worsening of symptoms, more commonly referred to as pulmonary exacerbations. Despite this being a common event, there is still no standardized definition of an exacerbation. A recent set of guidelines from the CF Foundation Pulmonary Therapies Committee on the treatment of exacerbations noted the paucity of data supporting commonly used therapies. This review describes our current understanding of pulmonary exacerbations and the therapies used to treat them. Recent findings The treatment of an exacerbation is intended to resolve the worsened symptoms and to restore the lung function that is commonly lost in the acute presentation. A most striking finding is the observation that for many patients there is no restoration of lung function, suggesting we either need better therapies to prevent exacerbations or better treatment of exacerbations. Summary We have established recommendations on specific treatment of a pulmonary exacerbation and have outlined the areas where we need better information on appropriate therapies. Once we have a standardized definition of an exacerbation, we can proceed with clinical trials of therapies specific for its treatment.
引用
收藏
页码:442 / 447
页数:6
相关论文
共 53 条
  • [21] Pulmonary Complications of Cystic Fibrosis
    Flume, Patrick A.
    [J]. RESPIRATORY CARE, 2009, 54 (05) : 618 - 625
  • [22] Flume PA, 2009, RESP CARE, V54, P522
  • [23] Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations
    Fothergill, Joanne L.
    Mowat, Eilidh
    Ledson, Martin J.
    Walshaw, Martin J.
    Winstanley, Craig
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2010, 59 (04) : 472 - 481
  • [24] EFFECT OF AEROSOLIZED RECOMBINANT HUMAN DNASE ON EXACERBATIONS OF RESPIRATORY SYMPTOMS AND ON PULMONARY-FUNCTION IN PATIENTS WITH CYSTIC-FIBROSIS
    FUCHS, HJ
    BOROWITZ, DS
    CHRISTIANSEN, DH
    MORRIS, EM
    NASH, ML
    RAMSEY, BW
    ROSENSTEIN, BJ
    SMITH, AL
    WOHL, ME
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (10) : 637 - 642
  • [25] Pathophysiology and management of pulmonary infections in cystic fibrosis
    Gibson, RL
    Burns, JL
    Ramsey, BW
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (08) : 918 - 951
  • [26] Managing acute on chronic respiratory failure: a guide to non-invasive ventilation
    Goldring, J. J. P.
    Wedzicha, J. A.
    [J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 2008, 69 (08) : 444 - 449
  • [27] Goss Christopher H, 2007, Proc Am Thorac Soc, V4, P378, DOI 10.1513/pats.200703-039BR
  • [28] Exacerbations in cystic fibrosis •1:: Epidemiology and pathogenesis
    Goss, Christopher H.
    Burns, Jane L.
    [J]. THORAX, 2007, 62 (04) : 360 - 367
  • [29] Sputum and serum calprotectin are useful biomarkers during CF exacerbation
    Gray, R. D.
    Imrie, M.
    Boyd, A. C.
    Porteous, D.
    Innes, J. A.
    Greening, A. P.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2010, 9 (03) : 193 - 198
  • [30] Plasma TGF-β1 in Pediatric Cystic Fibrosis: Potential Biomarker of Lung Disease and Response to Therapy
    Harris, William T.
    Muhlebach, Marianne S.
    Oster, Robert A.
    Knowles, Michael R.
    Clancy, J. P.
    Noah, Terry L.
    [J]. PEDIATRIC PULMONOLOGY, 2011, 46 (07) : 688 - 695